NYB.AI Awarded First Prize at SuperAI Genesis Global Contest

Nanyang Biologics (NYB.AI) was awarded 1st Prize at the prestigious SuperAI Genesis Startup Competition, selected from a pool of over 700 startups spanning more than 100 countries.  

The SuperAI Genesis competition, known for spotlighting the most promising AI-driven ventures globally, saw participation from innovators across North America, Europe, Asia-Pacific, Latin America, Africa, and the Middle East in its inaugural edition. NYB.AI’s groundbreaking approach to AI-driven drug discovery, especially its focus on nature-derived compounds and strong regional applicability captivated judges and audiences alike.

Fischer Medical Ventures Ltd (formerly Fischer Chemic Ltd), a pioneering force in the healthcare industry known for its affordable and accessible medical imaging technologies, cutting-edge innovations, and AI-powered software solutions, is a strategic joint-venture partner of NYB.AI and support the development of their transformative nutraceuticals derived from natural plants and herbs, with the goal of revolutionizing healthcare through innovative, evidence-based products.

A Transformative Approach to Drug Discovery

NYB.AI impressed the judging panel of SuperAI Genesis with its proprietary DTIGN platform (Drug‑Target Interaction Graph Neural Network). By combining graph neural networks with molecular docking, the platform predicts drug-target interactions with high precision, especially in compounds sourced from Southeast Asia’s rich biodiversity—an area traditionally underexplored by Western pharma.

Key Advantages of NYB.AI’s Platform:

·        25% higher accuracy compared to the next-best method (as recognized by IEEE Magazine)

·        10× faster model training, reducing computation time from 80 to 10 hours

·        8× faster molecular docking, with time cut from 70 to 8 hours

·        ~64× improvement in hit-rate efficiency and a 44.8% increase in bioactivity prediction accuracy

These advantages translate into accelerated drug development timelines, significant cost savings, and greater success rates — a game-changer for biotech R&D.

Commercial Momentum and Industry Partnerships

NYB.AI’s rapid rise is also supported by major industry partners, including NVIDIA, Johnson & Johnson Innovation – JLABS, Equinix and Hewlett Packard Enterprise (HPE).   The company has been selected to present at NVIDIA’s GTC 2025, further validating its technology’s impact and scalability.

 Visionary Leadership with Global Impact

Founded by scientists from Nanyang Technological University (NTU) with real-world experience in pharmaceutical R&D, NYB.AI combines deep domain knowledge with a forward-thinking vision. Beyond pharmaceuticals, the company’s platform has applications in nutraceuticals, beauty, and animal health.

Judges’ Verdict: Innovation, Market Potential, and Scalability

The SuperAI Genesis judges praised NYB.AI for excelling across all key evaluation metrics:

·        Innovation: Unique application of GNNs to natural compound discovery

·        Market Potential: Strong applicability across drug pipelines, supplements, and wellness

·        Scalability: Proven partnerships and robust AI infrastructure

Mr. Ravindran Govindan, Executive Chairman & MD of Fischer Medical Ventures Ltd, celebrates the win: “We are honoured to be recognized at SuperAI Genesis. This award reflects the two companies’ commitment to unlock the molecular secrets of Indian and Southeast Asian herbs, bringing them to global markets faster and more affordably.  We believe there are untapped treasures in Indian traditional medicine, and NYB.AI is here to translate that heritage into modern therapeutics and wellness solutions. We have already at this point uncovered an Indian traditional herb which can help treatment of mental health - a great breakthrough!”